CClinicalTrials.gg
CompletedNCT02410785Updated Jan 28, 2016

Efficacy of Polyglucosamine for Weight Loss

An interventional study of Polyglucosamine and Placebo in Overweight and Obesity, sponsored by Certmedica International GmbH. Completed at 2 sites in 2 countries. Open to participants aged 21 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-28.

Sponsored by Certmedica International GmbH · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The polyglucosamine, specification L112 is a medical device and in this clinical trial used for weight reduction of overweight and obese participants. The rationale for this study is to show that overweight can be reduced by taking 2 times daily 2 tablets with the main meals with the highest fat content.

Read the detailed description

To have a comparable diet condition, all participants in both groups had to follow the recommendations of the German clinical practice guidelines on the management and prevention of obesity.

One group had to take the polyglucosamine tablets and the other group placebo tablets for at least 24 weeks. It is known, that polyglucosamine is a fat binder acting in a physical-chemical manner, the positive charged fiber is bound to the negative charged dietary fat and this complex in unable to pass the gut wall into the body but is naturally excreted, hence this energy is not available. Therefore, this medical device should show a measurable reduction in body weight.

02

Conditions studied

  • Overweight and Obesity

Keywords

  • obesity,
  • body weight,
  • overweight,
  • weight loss,
  • polyglucosamine,
  • L112
  • caloric restriction
  • physical activity
03

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI > 26 and \< 45
  • waist circumference of more than 88 cm for women and greater than 102 for men.

Exclusion criteria

Exclusion Criteria:

  • pregnancy or breast-feeding, alcohol abuse, drug abuse or drug addiction, inability to fulfill the criteria of the trial protocol, cancer diseases, malignant tumors, pre-existence of chronic intestinal disease and known hypersensitivity reactions to crustaceans
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
115 participants (actual)

Study arms

  • Active comparator
    Medical device polyglucosamine

    2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.

    Device: Polyglucosamine

  • Placebo comparator
    Placebo

    2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.

    Other: Placebo

Interventions

  • DevicePolyglucosamine

    ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans

  • OtherPlacebo

    Placebo tablet

05

What researchers measure

Primary outcomes

  1. Number of participants who could reduce their body weight by 5 or more per cent compared to the initial body weight.

    Time frame: 24 weeks

Secondary outcomes

  1. Change of body weight in kg

    Time frame: 24 weeks

  2. Change of BMI

    Time frame: 24 weeks

  3. Reduction of waist circumference

    Time frame: 24 weeks

06

Study locations

2 sites
  • Salztal Klinik GmbH
    Bad Soden-Salmünster, Hessia 63628, Germany
  • MAP Center
    Rende, Cosenza 87036, Italy
07

References and documents

Publications

  • Pokhis K, Bitterlich N, Cornelli U, Cassano G. Efficacy of polyglucosamine for weight loss-confirmed in a randomized double-blind, placebo-controlled clinical investigation. BMC Obes. 2015 Jun 10;2:25. doi: 10.1186/s40608-015-0053-5. eCollection 2015. PubMed 26217540 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT02410785
Lead sponsor
Certmedica International GmbH
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Aug 2009
Primary completion
Oct 2009
Completion
Oct 2010
Last update
Jan 28, 2016

Study contacts

Karina Pokhis, MD
principal investigator · Salztal Klinik GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion